Erratum: Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial (The Lancet (2017) 389(10086) (2304–2316) (S0140673617300685) (10.1016/S0140-6736(17)30068-5));Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial

The Lancet

Volumn 389, Issue 10086, 2017, Pages 2304-2316

  Jørgensen, Kristin K ^a   Olsen, Inge C ^b   Goll, Guro L ^b   Lorentzen, Merete ^c   Bolstad, Nils ^c   Haavardsholm, Espen A ^b,d   Lundin, Knut E A ^c,d,e   Mørk, Cato ^f   Jahnsen, Jørgen ^a,d   Kvien, Tore K ^b,d   Berset, Ingrid P ^g   Fevang, Bjørg TS ^g   Florholmen, Jon ^g   Kalstad, Synøve ^g   Mørk, Nils J ^g   Ryggen, Kristin ^g   Tveit, Kåre S ^g   Sæther, Sigrun K ^g   Gulbrandsen, Bjørn ^g   Hagfors, Jon ^g   Waksvik, Kenneth ^g   Warren, David ^g   Henanger, Karoline J ^g   Asak, Øivind ^g   Baigh, Somyeh ^g   Blomgren, Ingrid M ^g   Bruun, Trude J ^g   Dvergsnes, Katrine ^g   Frigstad, Svein O ^g   Gjesdal, Clara G ^g   Grandaunet, Berit H J ^g   Hansen, Inger M ^g   Hatten, Ingvild S H ^g   Huppertz Hauss, Gert ^g   Henriksen, Magne ^g   Hoie, Sunniva S ^g   Krogh, Jan ^g   Kruse, Julia R ^g   Ljoså, Maud Kristine A ^g   Midtgard, Irina P ^g   Mielnik, Pawel ^g   Moum, Bjørn ^g   Noraberg, Geir ^g   Poyan, Armin ^g   Prestegård, Ulf ^g   Rashid, Haroon U ^g   Rydning, Jan Henrik ^g   Sagatun, Liv ^g   Seeberg, Kathrine A ^g   Skjetne, Kristine ^g   Strand, Eldri K ^g   Stray, Hilde ^g   Stray, Njaal ^g   Torp, Roald ^g   Vold, Cecilia ^g   Ystrøm, Carl M ^g   Zettel, Camilla C ^g   more..

^a AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^b DIAKONHJEMMET HOSPITAL   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

^e UNIVERSITY OF OSLO   (Norway)

^f NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^g NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIOSIMILAR AGENT; CT P 13; INFLIXIMAB; UNCLASSIFIED DRUG; CT-P13; GASTROINTESTINAL AGENT; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ABSCESS; ACUTE HEART INFARCTION; ADULT; ANUS DISEASE; ARTHRALGIA; ARTHRITIS; ARTICLE; ATRIAL FIBRILLATION; BLADDER CANCER; BREAST CANCER; CEREBROVASCULAR ACCIDENT; CHOLECYSTITIS; CHOLELITHIASIS; CONTROLLED STUDY; CROHN DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPLASIA; FAINTNESS; FEMALE; FLU LIKE SYNDROME; GASTROENTERITIS; GINGIVA DISEASE; GOUT; HEADACHE; HUMAN; INFORMED CONSENT; INFUSION RELATED REACTION; KIDNEY CYST; MAJOR CLINICAL STUDY; MALE; MELENA; MULTICENTER STUDY; NEPHROLITHIASIS; PANCREATITIS; PERITONITIS; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE DISEASE; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL; RASH; RESPIRATORY TRACT INFECTION; RETINA DETACHMENT; RHINOPHARYNGITIS; SINUSITIS; SPONDYLARTHRITIS; THORAX PAIN; TONSILLITIS; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; CLINICAL TRIAL; ECONOMICS; INFLAMMATORY BOWEL DISEASES; MIDDLE AGED; NORWAY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; BIOSIMILAR PHARMACEUTICALS; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; INFLIXIMAB; MALE; MIDDLE AGED; NORWAY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 85019086175     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(17)31423-X     Document Type: Erratum

References (31)

1. Kuek, A, Hazleman, BL, Ostor, AJ, Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad Med J 83 (2007), 251–260.
2. Putrik, P, Ramiro, S, Kvien, TK, et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis 73 (2014), 198–206.
3. Park, W, Hrycaj, P, Jeka, S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 72 (2013), 1605–1612.
4. Yoo, DH, Hrycaj, P, Miranda, P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 72 (2013), 1613–1620.
5. Schneider, CK, Biosimilars in rheumatology: the wind of change. Ann Rheum Dis 72 (2013), 315–318.
6. Dorner, T, Strand, V, Cornes, P, et al. The changing landscape of biosimilars in rheumatology. Ann Rheum Dis 75 (2016), 974–982.
7. Weise, M, Kurki, P, Wolff-Holz, E, Bielsky, MC, Schneider, CK, Biosimilars: the science of extrapolation. Blood 124 (2014), 3191–3196.
8. Danese, S, Gomollon, F, Governing Board and Operational Board of ECCO. ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). J Crohns Colitis 7 (2013), 586–589.
9. Ben-Horin, S, Vande-Casteele, N, Schreiber, S, Lakatos, PL, Biosimilars in inflammatory bowel disease: facts and fears of extrapolation. Clin Gastroenterol Hepatol 14 (2016), 1685–1696.
10. Blauvelt, A, Puig, L, Chimenti, S, et al. Biosimilars for psoriasis: clinical studies to determine similarity. Br J Dermatol, 2016, 10.1111/bjd.15067 published online Sept 17.
11. Feagan, BG, Choquette, D, Ghosh, S, et al. The challenge of indication extrapolation for infliximab biosimilars. Biologicals 42 (2014), 177–183.
12. Gecse, KB, Lakatos, PL, Biosimilar monoclonal antibodies for inflammatory bowel disease: current comfort and future prospects. Drugs 76 (2016), 1413–1420.
13. Dorner, T, Kay, J, Biosimilars in rheumatology: current perspectives and lessons learnt. Nat Rev Rheumatol 11 (2015), 713–724.
14. Braun, J, Kudrin, A, Switching to biosimilar infliximab (CT-P13): evidence of clinical safety, effectiveness and impact on public health. Biologicals 44 (2016), 257–266.
15. Buer, LC, Moum, BA, Cvancarova, M, Warren, DJ, Medhus, AW, Hoivik, ML, Switching from Remicade(R) to Remsima(R) is safe and feasible: a prospective, open-label study. J Crohns Colitis, 2016, 10.1093/ecco-jcc/jjw166 published online Sept 22.
16. Smits, LJ, Derikx, LA, de Jong, DJ, et al. Clinical outcomes following a switch from Remicade(R) to the biosimilar CT-P13 in inflammatory bowel disease patients: a prospective observational cohort study. J Crohns Colitis 10 (2016), 1287–1293.
17. Dapavo, P, Vujic, I, Fierro, MT, Quaglino, P, Sanlorenzo, M, The infliximab biosimilar in the treatment of moderate to severe plaque psoriasis. J Am Acad Dermatol 75 (2016), 736–739.
18. Glintborg, B, Juul Sørensen, I, Vendelbo Jensen, D, et al. Three months' clinical outcomes from a nationwide non-medical switch from originator to biosimilar infliximab in patients with inflammatory arthritis, results from the DANBIO registry. Ann Rheum Dis, 75(suppl 2), 2016, 142.
19. Park, W, Yoo, DH, Miranda, P, et al. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann Rheum Dis, 2016, 10.1136/annrheumdis-2015-208783 published online April 26.
20. Yoo, DH, Prodanovic, N, Jaworski, J, et al. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann Rheum Dis, 2016, 10.1136/annrheumdis-2015-208786 published online April 29.
21. Harvey, RF, Bradshaw, MJ, Measuring Crohn's disease activity. Lancet 315 (1980), 1134–1135.
22. Schroeder, KW, Tremaine, WJ, Ilstrup, DM, Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study. N Engl J Med 317 (1987), 1625–1629.
23. Machado, P, Landewe, R, Lie, E, et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 70 (2011), 47–53.
24. Prevoo, ML, van 't Hof, MA, Kuper, HH, van Leeuwen, MA, van de Putte, LB, van Riel, PL, Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38 (1995), 44–48.
25. Fredriksson, T, Pettersson, U, Severe psoriasis—oral therapy with a new retinoid. Dermatologica 157 (1978), 238–244.
26. Schaeverbeke, T, Truchetet, ME, Kostine, M, Barnetche, T, Bannwarth, B, Richez, C, Immunogenicity of biologic agents in rheumatoid arthritis patients: lessons for clinical practice. Rheumatology 55 (2016), 210–220.
27. European Medicines Agency. Assessment report: Remsima. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002576/WC500151486.pdf, June 27, 2013 (accessed Feb 19, 2017).
28. Choe, JY, Prodanovic, N, Niebrzydowski, J, et al. A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis 76 (2017), 58–64.
29. Emery, P, Vencovsky, J, Sylwestrzak, A, et al. A phase III randomised, doubleblind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis 76 (2017), 51–57.
30. Griffiths, CE, Thaci, D, Gerdes, S, et al. The EGALITY study: a confirmatory, randomised, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, versus the originator product in patients with moderate to severe chronic plaque-type psoriasis. Br J Dermatol, 2016, 10.1111/bjd.15152 published online Oct 27.
31. FDA Briefing document: Arthritis Advisory Committee meeting. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/arthritisadvisorycommittee/ucm484859.pdf (accessed Jan 3, 2017).